RNAi Firms Unite Rather than Fight

In the hot new field of RNAi research, both Alnylam Pharmaceuticals and Ribopharma felt they controlled vital intellectual property. To end uncertainty offputting to potential partners and investors, and leverage the commercial head-start of Ribopharma, the companies decided to merge and go forward as Alnylam.